Mira Pharmaceuticals (MIRA) Liabilities and Shareholders Equity (2022 - 2025)

Mira Pharmaceuticals (MIRA) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $11.1 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 279.52% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.0 million (up 90.9% YoY) and the FY2025 annual result came in at $11.1 million, up 279.52% from the prior year.
• Liabilities and Shareholders Equity advanced to $11.1 million in Q4 2025 per MIRA's latest filing, from $7.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $11.1 million in Q4 2025, with the low at $858074.0 in Q4 2022.
• Average Liabilities and Shareholders Equity over 4 years is $4.6 million, with a median of $3.8 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity jumped 474.83% in 2023 and plunged 63.23% in 2025.
• Mira Pharmaceuticals' Liabilities and Shareholders Equity stood at $858074.0 in 2022, then jumped by 474.83% to $4.9 million in 2023, then tumbled by 40.74% to $2.9 million in 2024, then surged by 279.52% to $11.1 million in 2025.
• Business Quant data shows MIRA's Liabilities and Shareholders Equity at $11.1 million in Q4 2025, $7.6 million in Q3 2025, and $868318.0 in Q2 2025.